Midwest Professional Planners LTD. purchased a new stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 20,874 shares of the financial services provider’s stock, valued at approximately $3,523,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in iShares Biotechnology ETF by 46,806.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 46,906 shares of the financial services provider’s stock valued at $7,927,000 after acquiring an additional 46,806 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in iShares Biotechnology ETF in the third quarter valued at about $1,907,000. Central Pacific Bank Trust Division grew its position in iShares Biotechnology ETF by 296,500.0% in the fourth quarter. Central Pacific Bank Trust Division now owns 14,830 shares of the financial services provider’s stock valued at $2,503,000 after acquiring an additional 14,825 shares during the last quarter. Florin Court Capital LLP bought a new position in iShares Biotechnology ETF in the third quarter valued at about $11,116,000. Finally, Assetmark Inc. grew its position in iShares Biotechnology ETF by 150,979.6% in the fourth quarter. Assetmark Inc. now owns 74,029 shares of the financial services provider’s stock valued at $12,494,000 after acquiring an additional 73,980 shares during the last quarter. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
NASDAQ IBB opened at $164.32 on Wednesday. iShares Biotechnology ETF has a twelve month low of $119.78 and a twelve month high of $179.64. The business’s fifty day moving average is $169.08 and its 200 day moving average is $169.75.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Further Reading
- Five stocks we like better than iShares Biotechnology ETF
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.
